{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:17:42Z","timestamp":1793049462484,"version":"4.5.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T00:00:00Z","timestamp":1719446400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001779","name":"Monash University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001779","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The COVID-19 pandemic raised concern amongst clinicians that disease-modifying therapies (DMT), particularly anti-CD20 monoclonal antibodies (mAb) and fingolimod, could worsen COVID-19 in people with multiple sclerosis (pwMS). This study aimed to examine DMT prescribing trends pre- and post-pandemic onset.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A multi-centre longitudinal study with 8,771 participants from MSBase was conducted. Two time periods were defined: pre-pandemic (March 11 2018\u2013March 10 2020) and post-pandemic onset (March 11 2020\u201311 March 2022). The association between time and prescribing trends was analysed using multivariable mixed-effects logistic regression. DMT initiation refers to first initiation of any DMT, whilst DMT switches indicate changing regimen within 6\u00a0months of last use.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Post-pandemic onset, there was a significant increase in DMT initiation\/switching to natalizumab and cladribine [(Natalizumab-initiation: OR 1.72, 95% CI 1.39\u20132.13; switching: OR 1.66, 95% CI 1.40\u20131.98), (Cladribine-initiation: OR 1.43, 95% CI 1.09\u20131.87; switching: OR 1.67, 95% CI 1.41\u20131.98)]. Anti-CD20mAb initiation\/switching decreased in the year of the pandemic, but recovered in the second year, such that overall odds increased slightly post-pandemic (initiation: OR 1.26, 95% CI 1.06\u20131.49; Switching: OR 1.15, 95% CI 1.02\u20131.29. Initiation\/switching of fingolimod, interferon-beta, and alemtuzumab significantly decreased [(Fingolimod-initiation: OR 0.55, 95% CI 0.41\u20130.73; switching: OR 0.49, 95% CI 0.41\u20130.58), (Interferon-gamma-initiation: OR 0.48, 95% CI 0.41\u20130.57; switching: OR 0.78, 95% CI 0.62\u20130.99), (Alemtuzumab-initiation: OR 0.27, 95% CI 0.15\u20130.48; switching: OR 0.27, 95% CI 0.17\u20130.44)].<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Post-pandemic onset, clinicians preferentially prescribed natalizumab and cladribine over anti-CD20 mAbs and fingolimod, likely to preserve efficacy but reduce perceived immunosuppressive risks. This could have implications for disease progression in pwMS. Our findings highlight the significance of equitable DMT access globally, and the importance of evidence-based decision-making in global health challenges.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s00415-024-12518-7","type":"journal-article","created":{"date-parts":[[2024,6,27]],"date-time":"2024-06-27T06:02:55Z","timestamp":1719468175000},"page":"5813-5824","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A multi-centre longitudinal study analysing multiple sclerosis disease-modifying therapy prescribing patterns during the COVID-19 pandemic"],"prefix":"10.1007","volume":"271","author":[{"given":"Anoushka P.","family":"Lal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi Chao","family":"Foong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Sanfilippo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Spelman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Louise","family":"Rath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Levitz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marzena","family":"Fabis-Pedrini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Foschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Habek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kalincik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Izanne","family":"Roos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeannette","family":"Lechner-Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nevin","family":"John","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aysun","family":"Soysal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuele","family":"D\u2019Amico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Riadh","family":"Gouider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saloua","family":"Mrabet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katrin","family":"Gross-Paju","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sim\u00f3n","family":"C\u00e1rdenas-Robledo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdorreza Naser","family":"Moghadasi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Jose","family":"Sa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Orla","family":"Gray","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiwon","family":"Oh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Reddel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudarshini","family":"Ramanathan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Talal","family":"Al-Harbi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayse","family":"Altintas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Todd A.","family":"Hardy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serkan","family":"Ozakbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raed","family":"Alroughani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Allan G.","family":"Kermode","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Surcinelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guy","family":"Laureys","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Eichau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Prat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Girard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Duquette","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne","family":"Hodgkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Ramo-Tello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davide","family":"Maimone","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela","family":"McCombe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele","family":"Spitaleri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jose Luis","family":"Sanchez-Menoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehmet Fatih","family":"Yetkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed Mohammad","family":"Baghbanian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rana","family":"Karabudak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdullah","family":"Al-Asmi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gregor Brecl","family":"Jakob","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia J.","family":"Khoury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masoud","family":"Etemadifar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vincent","family":"van Pesch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katherine","family":"Buzzard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Taylor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helmut","family":"Butzkueven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4278-7003","authenticated-orcid":false,"given":"Anneke","family":"Van der Walt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,27]]},"reference":[{"key":"12518_CR1","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/NXI.0000000000001001","volume":"8","author":"M Barzegar","year":"2021","unstructured":"Barzegar M et al (2021) COVID-19 among patients with multiple sclerosis: a systematic review. Neurol Neuroimmunol Neuroinflamm 8:4","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11","key":"12518_CR2","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.1177\/13524585221094218","volume":"28","author":"MW Leung","year":"2022","unstructured":"Leung MW et al (2022) Mapping the risk of infections in patients with multiple sclerosis: a multi-database study in the United Kingdom Clinical Practice Research Datalink GOLD and Aurum. Mult Scler 28(11):1808\u20131818","journal-title":"Mult Scler"},{"key":"12518_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jns.2020.117147","volume":"418","author":"F Chaudhry","year":"2020","unstructured":"Chaudhry F et al (2020) COVID-19 in multiple sclerosis patients and risk factors for severe infection. J Neurol Sci 418:117147","journal-title":"J Neurol Sci"},{"issue":"9","key":"12518_CR4","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1001\/jamaneurol.2020.2581","volume":"77","author":"C Louapre","year":"2020","unstructured":"Louapre C et al (2020) Clinical characteristics and outcomes in patients with coronavirus disease 2019 and multiple sclerosis. JAMA Neurol 77(9):1079\u20131088","journal-title":"JAMA Neurol"},{"issue":"22","key":"12518_CR5","doi-asserted-by":"publisher","first-page":"949","DOI":"10.1212\/WNL.0000000000009507","volume":"94","author":"W Brownlee","year":"2020","unstructured":"Brownlee W et al (2020) Treating multiple sclerosis and neuromyelitis optica spectrum disorder during the COVID-19 pandemic. Neurology 94(22):949\u2013952","journal-title":"Neurology"},{"issue":"9","key":"12518_CR6","doi-asserted-by":"publisher","first-page":"493","DOI":"10.1038\/s41582-020-0385-8","volume":"16","author":"C Korsukewitz","year":"2020","unstructured":"Korsukewitz C, Reddel SW, Bar-Or A, Wiendl H (2020) Neurological immunotherapy in the era of COVID-19\u2014looking for consensus in the literature. Nat Rev Neurol 16(9):493\u2013505","journal-title":"Nat Rev Neurol"},{"key":"12518_CR7","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102073","volume":"39","author":"G Giovannoni","year":"2020","unstructured":"Giovannoni G et al (2020) The COVID-19 pandemic and the use of MS disease-modifying therapies. Mult Scler Relat Disord 39:102073","journal-title":"Mult Scler Relat Disord"},{"key":"12518_CR8","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/NXI.0000000000000761","volume":"7","author":"JR Berger","year":"2020","unstructured":"Berger JR, Brandstadter R, Bar-Or A (2020) COVID-19 and MS disease-modifying therapies. Neurol Neuroimmunol Neuroinflamm 7:4","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12518_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102195","volume":"43","author":"F Safavi","year":"2020","unstructured":"Safavi F, Nourbakhsh B, Azimi AR (2020) B-cell depleting therapies may affect susceptibility to acute respiratory illness among patients with multiple sclerosis during the early COVID-19 epidemic in Iran. Mult Scler Relat Disord 43:102195","journal-title":"Mult Scler Relat Disord"},{"issue":"7","key":"12518_CR10","doi-asserted-by":"publisher","first-page":"1647","DOI":"10.1007\/s10072-020-04519-x","volume":"41","author":"G Dalla Costa","year":"2020","unstructured":"Dalla Costa G et al (2020) Real-time assessment of COVID-19 prevalence among multiple sclerosis patients: a multicenter European study. Neurol Sci 41(7):1647\u20131650","journal-title":"Neurol Sci"},{"issue":"6","key":"12518_CR11","doi-asserted-by":"publisher","first-page":"e2319766","DOI":"10.1001\/jamanetworkopen.2023.19766","volume":"6","author":"E Januel","year":"2023","unstructured":"Januel E et al (2023) Association between anti-CD20 therapies and COVID-19 severity among patients with relapsing-remitting and progressive multiple sclerosis. JAMA Netw Open 6(6):e2319766\u2013e2319766","journal-title":"JAMA Netw Open"},{"key":"12518_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103358","volume":"57","author":"I Schiavetti","year":"2022","unstructured":"Schiavetti I et al (2022) Severe outcomes of COVID-19 among patients with multiple sclerosis under anti-CD-20 therapies: a systematic review and meta-analysis. Multiple Scler Relat Disord 57:103358","journal-title":"Multiple Scler Relat Disord"},{"key":"12518_CR13","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2022.103912","volume":"63","author":"G Bsteh","year":"2022","unstructured":"Bsteh G et al (2022) Has the pandemic changed treatment strategy in multiple sclerosis? Mult Scler Relat Disord 63:103912","journal-title":"Mult Scler Relat Disord"},{"key":"12518_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2023.104575","volume":"71","author":"R Zaheer","year":"2023","unstructured":"Zaheer R et al (2023) Impact of COVID-19 on prescribing patterns and treatment selection of disease modifying therapies in multiple sclerosis. Mult Scler Relat Disord 71:104575","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"12518_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/j.ncl.2023.06.006","volume":"42","author":"JD Krett","year":"2024","unstructured":"Krett JD, Salter A, Newsome SD (2024) Era of COVID-19 in multiple sclerosis care. Neurol Clin 42(1):319\u2013340","journal-title":"Neurol Clin"},{"issue":"11","key":"12518_CR16","doi-asserted-by":"publisher","first-page":"1229","DOI":"10.1136\/jnnp-2021-328340","volume":"93","author":"W Thomas","year":"2022","unstructured":"Thomas W et al (2022) Impact of the COVID-19 pandemic on the prescription of disease-modifying therapy for multiple sclerosis in England: a nationwide study. J Neurol Neurosurg Psychiatry 93(11):1229","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"8","key":"12518_CR17","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1002\/acn3.51408","volume":"8","author":"MP Sormani","year":"2021","unstructured":"Sormani MP et al (2021) DMTs and Covid-19 severity in MS: a pooled analysis from Italy and France. Ann Clin Transl Neurol 8(8):1738\u20131744","journal-title":"Ann Clin Transl Neurol"},{"issue":"7","key":"12518_CR18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.1177\/13524585211026272","volume":"28","author":"T Spelman","year":"2021","unstructured":"Spelman T et al (2021) Increased rate of hospitalisation for COVID-19 among rituximab-treated multiple sclerosis patients: a study of the Swedish multiple sclerosis registry. Mult Scler J 28(7):1051\u20131059","journal-title":"Mult Scler J"},{"issue":"5","key":"12518_CR19","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1007\/s13311-022-01289-6","volume":"19","author":"A Zangh\u00ec","year":"2022","unstructured":"Zangh\u00ec A et al (2022) Is it time for ocrelizumab extended interval dosing in relapsing remitting MS? Evidence from an Italian multicenter experience during the COVID-19 pandemic. Neurotherapeutics 19(5):1535\u20131545","journal-title":"Neurotherapeutics"},{"issue":"17","key":"12518_CR20","doi-asserted-by":"publisher","first-page":"6251","DOI":"10.1212\/WNL.0000000000206347","volume":"102","author":"A Bisecco","year":"2024","unstructured":"Bisecco A et al (2024) Covid-19 outbreak in Italy: an opportunity to evaluate extended interval dosing of ocrelizumab in MS patients (P2\u20136010). Neurology 102(17):6251","journal-title":"Neurology"},{"issue":"2","key":"12518_CR21","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","volume":"17","author":"AJ Thompson","year":"2018","unstructured":"Thompson AJ et al (2018) Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. Lancet Neurol 17(2):162\u2013173","journal-title":"Lancet Neurol"},{"key":"12518_CR22","first-page":"4","volume":"2","author":"YC Foong","year":"2024","unstructured":"Foong YC et al (2024) Comparing ocrelizumab to interferon\/glatiramer acetate in people with multiple sclerosis over age 60. J Neurol Neurosurg Psychiatry 2:4","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"12518_CR23","doi-asserted-by":"publisher","first-page":"1477","DOI":"10.1007\/s40120-023-00520-6","volume":"12","author":"F Carlini","year":"2023","unstructured":"Carlini F et al (2023) Cladribine tablets mode of action, learning from the pandemic: a narrative review. Neurol Therapy 12(5):1477\u20131490","journal-title":"Neurol Therapy"},{"issue":"8","key":"12518_CR24","doi-asserted-by":"publisher","first-page":"2697","DOI":"10.1007\/s00415-020-10309-4","volume":"268","author":"P Preziosa","year":"2021","unstructured":"Preziosa P et al (2021) COVID-19 in cladribine-treated relapsing-remitting multiple sclerosis patients: a monocentric experience. J Neurol 268(8):2697\u20132699","journal-title":"J Neurol"},{"key":"12518_CR25","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102452","volume":"45","author":"M De Angelis","year":"2020","unstructured":"De Angelis M et al (2020) Mild or no COVID-19 symptoms in cladribine-treated multiple sclerosis: two cases and implications for clinical practice. Mult Scler Relat Disord 45:102452","journal-title":"Mult Scler Relat Disord"},{"key":"12518_CR26","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.msard.2019.01.038","volume":"29","author":"G Comi","year":"2019","unstructured":"Comi G et al (2019) Effect of cladribine tablets on lymphocyte reduction and repopulation dynamics in patients with relapsing multiple sclerosis. Mult Scler Relat Disord 29:168\u2013174","journal-title":"Mult Scler Relat Disord"},{"issue":"1","key":"12518_CR27","doi-asserted-by":"publisher","first-page":"462","DOI":"10.1186\/s12883-021-02421-3","volume":"21","author":"CG Chisari","year":"2021","unstructured":"Chisari CG et al (2021) Natalizumab administration in multiple sclerosis patients during active SARS-CoV-2 infection: a case series. BMC Neurol 21(1):462","journal-title":"BMC Neurol"},{"key":"12518_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2021.103345","volume":"57","author":"D Landi","year":"2022","unstructured":"Landi D et al (2022) Safety of Natalizumab infusion in multiple sclerosis patients during active SARS-CoV-2 infection. Mult Scler Relat Disord 57:103345","journal-title":"Mult Scler Relat Disord"},{"key":"12518_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102250","volume":"44","author":"C Aguirre","year":"2020","unstructured":"Aguirre C et al (2020) Covid-19 in a patient with multiple sclerosis treated with natalizumab: May the blockade of integrins have a protective role? Mult Scler Relat Disord 44:102250","journal-title":"Mult Scler Relat Disord"},{"key":"12518_CR30","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2020.104759","volume":"177","author":"CJ Sigrist","year":"2020","unstructured":"Sigrist CJ, Bridge A, Le Mercier P (2020) A potential role for integrins in host cell entry by SARS-CoV-2. Antiviral Res 177:104759","journal-title":"Antiviral Res"},{"issue":"3","key":"12518_CR31","doi-asserted-by":"publisher","first-page":"1557","DOI":"10.1007\/s10072-021-05846-3","volume":"43","author":"M Hada","year":"2022","unstructured":"Hada M, Mosholder AD, Leishear K, Perez-Vilar S (2022) Systematic review of risk of SARS-CoV-2 infection and severity of COVID-19 with therapies approved to treat multiple sclerosis. Neurol Sci 43(3):1557\u20131567","journal-title":"Neurol Sci"},{"issue":"19","key":"12518_CR32","doi-asserted-by":"publisher","first-page":"e1870","DOI":"10.1212\/WNL.0000000000012753","volume":"97","author":"S Simpson-Yap","year":"2021","unstructured":"Simpson-Yap S et al (2021) Associations of disease-modifying therapies with COVID-19 severity in multiple sclerosis. Neurology 97(19):e1870\u2013e1885","journal-title":"Neurology"},{"issue":"1","key":"12518_CR33","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1001\/jamaneurol.2014.3065","volume":"72","author":"AM Arvin","year":"2015","unstructured":"Arvin AM et al (2015) Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol 72(1):31\u201339","journal-title":"JAMA Neurol"},{"issue":"2","key":"12518_CR34","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1001\/jamaneurol.2019.3365","volume":"77","author":"G Luna","year":"2020","unstructured":"Luna G et al (2020) Infection risks among patients with multiple sclerosis treated with fingolimod, natalizumab, rituximab, and injectable therapies. JAMA Neurol 77(2):184\u2013191","journal-title":"JAMA Neurol"},{"key":"12518_CR35","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1212\/NXI.0000000000000753","volume":"7","author":"M Barzegar","year":"2020","unstructured":"Barzegar M et al (2020) COVID-19 infection in a patient with multiple sclerosis treated with fingolimod. Neurol Neuroimmunol Neuroinflamm 7:4","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"key":"12518_CR36","first-page":"1","volume":"9","author":"R Sullivan","year":"2021","unstructured":"Sullivan R et al (2021) COVID-19 infection in fingolimod- or siponimod-treated patients: case series. Neurol Neuroimmunol Neuroinflamm 9:1","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"12518_CR37","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.1039","volume":"11","author":"S Teymouri","year":"2023","unstructured":"Teymouri S et al (2023) The effect of Fingolimod on patients with moderate to severe COVID-19. Pharmacol Res Perspect 11(1):e01039","journal-title":"Pharmacol Res Perspect"},{"issue":"2","key":"12518_CR38","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1111\/cei.13495","volume":"202","author":"D Baker","year":"2020","unstructured":"Baker D et al (2020) COVID-19 vaccine-readiness for anti-CD20-depleting therapy in autoimmune diseases. Clin Exp Immunol 202(2):149\u2013161","journal-title":"Clin Exp Immunol"},{"key":"12518_CR39","doi-asserted-by":"publisher","DOI":"10.1016\/j.msard.2020.102439","volume":"45","author":"JR Ciotti","year":"2020","unstructured":"Ciotti JR, Valtcheva MV, Cross AH (2020) Effects of MS disease-modifying therapies on responses to vaccinations: a review. Mult Scler Relat Disord 45:102439","journal-title":"Mult Scler Relat Disord"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12518-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12518-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:17:46Z","timestamp":1725538666000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12518-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,27]]},"references-count":39,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12518"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12518-7","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,27]]},"assertion":[{"value":"4 May 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 June 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yi Chao Foong: reports a relationship with Biogen that includes: travel reimbursement. Tim Spelman: received compensation for serving on scientific advisory board for Biogen and speaker honoraria from Novartis. Marzena Fabis-Pedrini: received travel compensation from Merck. Matteo Foschi: received travel and meeting attendance support from Novartis, Biogen, Roche, Sanofi-Genzyme, and Merck. Mario Habek: participated as a clinical investigator and\/or received consultation and\/or speaker fees from Biogen, Sanofi-Genzyme, Merck, Novartis, Pliva\/Teva, Roche, Zentiva, Astra-Zeneca, TG Pharmaceuticals, and CNSystems. Tomas Kalincik: served on scientific advisory boards for the MS International Federation and the World Health Organization, BMS, Roche, Janssen, Sanofi-Genzyme, Novartis, Merck, and Biogen. He served on the steering committee for the Brain Atrophy Initiative by Sanofi-Genzyme, received conference travel support and\/or speaker honoraria from WebMD Global, Eisai, Novartis, Biogen, Roche, Sanofi-Genzyme, Teva, BioCSL, and Merck, and received research or educational event support from Biogen, Novartis, Genzyme, Roche, Celgene, and Merck. Izanne Roos: has served on scientific advisory boards and received conference travel support and\/or speaker honoraria from Roche, Novartis, Merck, and Biogen. Izanne Roos is supported by MS Australia and the Trish Multiple Sclerosis Research Foundation. Anneke van der Walt: served on advisory boards and receives unrestricted research grants from Novartis, Biogen, Merck, and Roche. She has received speaker\u2019s honoraria and travel support from Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia. Helmut Butzkueven: received institutional (Monash University) funding from Biogen, F. Hoffmann-La Roche Ltd, Merck, Alexion, CSL, and Novartis; has carried out contracted research for Novartis, Merck, F. Hoffmann-La Roche Ltd, and Biogen; has taken part in speakers\u2019 bureaus for Biogen, Genzyme, UCB, Novartis, F. Hoffmann-La Roche Ltd, and Merck; has received personal compensation from the Oxford Health Policy Forum for the Brain Health Steering Committee. Jeannette Lechner-Scott: received travel compensation from Novartis, Biogen, Roche, and Merck. Her institution receives honoraria for talks and advisory board commitments as well as research grants from Biogen, Merck, Roche, TEVA, and Novartis. Nevin John: is a PI on commercial MS studies sponsored by Novartis, Roche, Biogen, and Sanofi. He has received speaker\u2019s honoraria from Merck and conference travel and registration reimbursement from Novartis. \u201cEmanuele D'amico\u201d: has received speaker honoraria and consultant fees from Biogen-Idec, Novartis, Merck, Janssen, Bristol-Myers, Bayer, Sanofi-Genzyme, and Roche. Riadh Gouider: has received research grant and\/or advisory board honoraria from Biogen, Hikma, Merck, Roche, and Sanofi. He has no conflict of interest related to this study. Saloua Mrabet: has received a MENACTRIMS clinical fellowship grant (2020). Katrin Gross-Paju: received honoraria as a consultant on scientific advisory boards for Biogen, Roche, and Novartis; has received travel grants from Biogen, Roche, and Novartis; and has participated in clinical trials by Biogen, Merck, Sanofi, Roche, and Novartis. Sim\u00f3n C\u00e1rdenas-Robledo: has received travel expenses for scientific meetings from Biopas, Roche, Merck, and Genzyme; compensation for consulting services or participation on advisory boards from Merck, Biogen-Idec, Sanofi, and Novartis; lecture fees from Biopas, Novartis, Merck, Sanofi, Janssen, and Biogen-Idec; and research support from Biogen-Idec and Novartis. He is a subject editor on Multiple Sclerosis for Acta Neurol\u00f3gica Colombiana and a member of the editorial board of Frontiers of Neurology. Abdorreza Naser Moghadasi: has served on scientific advisory boards and received conference travel support and\/or speaker honoraria from Roche, Novartis, Genzyme, Merck, and Biogen. Maria Jose Sa: received consulting fees, speaker honoraria, and\/or travel expenses for scientific meetings from Alexion, Bayer Healthcare, Biogen, Bristol Myers Squibb, Celgene, Janssen, Merck-Serono, Novartis, Roche, Sanofi, and Teva. Orla Gray: received honoraria as a consultant on scientific advisory boards for Genzyme, Biogen, Merck, Roche, and Novartis; has received travel grants from Biogen, Merck, Roche, and Novartis; has participated in clinical trials by Biogen and Merck. Her institution has received research grant support from Biogen. Jiwon Oh: has received research funding from the MS Society of Canada, National MS Society, Brain Canada, Biogen, Roche, and EMD Serono (an affiliate of Merck KGaA); and personal compensation for consulting or speaking from Alexion, Biogen, Celgene (BMS), EMD Serono (an affiliate of Merck KGaA), Novartis, Roche, and Sanofi-Genzyme. Sudarshini Ramanathan: has received research funding from the National Health and Medical Research Council (NHMRC, Australia), the Petre Foundation, the Brain Foundation, the Royal Australasian College of Physicians, and the University of Sydney. She is supported by an NHMRC Investigator Grant (GNT2008339). She serves as a consultant on the International Steering Committee for a clinical trial led by UCB (NCT05063162). She is on the advisory board for educational activities led by Limbic Neurology. She has been an invited speaker for educational\/research sessions coordinated by Biogen, Alexion, Novartis, Excemed, and Limbic Neurology. She is on the medical advisory board (non-remunerated positions) of The MOG Project and the Sumaira Foundation. Ayse Altintas: received speaker honoraria from Novartis and Alexion. Todd A. Hardy: received speaker honoraria\/conference travel support or served on advisory boards for Bayer Schering, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Bristol Myers Squibb, and Teva. Raed Alroughani: received honoraria as a speaker and for serving on scientific advisory boards from Bayer, Biogen, GSK, Merck, Novartis, Roche, and Sanofi-Genzyme. Allan G Kermode: received speaker honoraria and scientific advisory board fees from Bayer, BioCSL, Biogen, Genzyme, Innate Immunotherapeutics, Merck, Novartis, Sanofi, Sanofi-Aventis, and Teva. Andrea Surcinelli: received travel and meeting attendance support from Novartis, Biogen, Roche, Merck, Bristol, Sanofi-Genzyme, Almirall, and Piam. Guy Laureys: received travel and\/or consultancy compensation from Sanofi-Genzyme, Roche, Teva, Merck, Novartis, Celgene, and Biogen. Sara Eichau: has received speaker honoraria and consultant fees from Biogen-Idec, Novartis, Merck, Janssen, Bristol-Myers, Bayer, Sanofi-Genzyme, Roche, and Teva. Pierre Duquette: served on editorial boards and has been supported to attend meetings by EMD, Biogen, Novartis, Genzyme, and TEVA Neuroscience. He holds grants from the CIHR and the MS Society of Canada and has received funding for investigator-initiated trials from Biogen, Novartis, and Genzyme. Suzanne Hodgkinson: has received consulting fees and speaker honoraria from Biogen, Novartis, Roche, and Merck, and has received grants for her institution from Biogen, Merck, Novartis, and Roche. Cristina Ramo-Tello: has received consulting fees, speaker honoraria, support for attending meetings and\/or travel, participation on advisory boards, and research grants for her institution from Biogen, Novartis, Sanofi, Bristol, Roche, Almirall, Janssen, Sandoz, and Merck. Davide Maimone: received speaker honoraria for the advisory board and travel grants from Alexion, Almirall, Bayer, Biogen, Bristol Myers Squibb, Merck, Novartis, Roche, Sanofi-Genzyme, and Teva. Pamela McCombe: received speakers fees and travel grants from Novartis, Biogen, T\u2019\u00e9valua, and Sanofi. Daniele Spitaleri: received honoraria as a consultant on scientific advisory boards by Bayer-Schering, Novartis, and Sanofi-Aventis, and compensation for travel from Novartis, Biogen, Sanofi-Aventis, Teva, and Merck. Jose Luis Sanchez-Menoyo: accepted travel compensation from Novartis, Merck, and Biogen; speaking honoraria from Biogen, Novartis, Sanofi, Merck, Almirall, Bayer, and Teva; and has participated in clinical trials by Biogen, Merck, and Roche. Seyed Mohammad Baghbanian: has served on scientific advisory boards and has received conference travel support and\/or speaker honoraria from several pharmaceutical companies, including Roche, Novartis, Merck, Cinnagen, Nanoalvand, and Biogen. Rana Karabudak: received consulting fees, payment, or honoraria for lectures, presentations, speakers bureaus, manuscript writing, or educational events; support for attending meetings and\/or travel; and participation on a data safety monitoring board or advisory board from Gen Turkey. Abdullah Al-Asmi: received personal compensation for serving as a scientific advisor or speaker\/moderator for Novartis, Biogen, Roche, Sanofi-Genzyme, and Merck. Gregor Brecl Jakob: participated as a clinical investigator and\/or received consultation and\/or speaker fees from Amgen, Astra-Zeneca, Biogen, Janssen, Lek, Merck, Novartis, Pliva\/Teva, Roche, Sanofi-Genzyme, and Swixx. Samia J. Khoury: received compensation for scientific advisory board activity from Merck and Roche, and received compensation for serving on the IDMC for Biogen. Vincent van Pesch: received travel grants from Merck Healthcare KGaA (Darmstadt, Germany), Biogen, Sanofi, Bristol Meyer Squibb, Almirall, and Roche. His institution has received research grants and consultancy fees from Roche, Biogen, Sanofi, Merck Healthcare KGaA (Darmstadt, Germany), Bristol Meyer Squibb, Janssen, Almirall, Novartis Pharma, and Alexion. Helmut Butzkueven: received institutional (Monash University) funding from Biogen, F. Hoffmann-La Roche Ltd, Merck, Alexion, CSL, and Novartis; has carried out contracted research for Novartis, Merck, F. Hoffmann-La Roche Ltd and Biogen; has taken part in speakers\u2019 bureaus for Biogen, Genzyme, UCB, Novartis, F. Hoffmann-La Roche Ltd and Merck; has received personal compensation from Oxford Health Policy Forum for the Brain Health Steering Committee. Anneke van der Walt: served on advisory boards and receives \nunrestricted research grants from Novartis, Biogen, Merck and Roche She has received speaker\u2019s honoraria and travel support from Novartis, Roche, and Merck. She receives grant support from the National Health and Medical Research Council of Australia and MS Research Australia. The remaining authors have nothing to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}